Clinical trials: Chronic Hepatitis, B Virus
Hepatitis B, Chronic, Fibrosis, Liver
Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes
An exploratory comparison of changes in liver fibrosis through glycemic control within and between groups after administration of Pioglitazone and Evogliptin in chronic hepatitis B patients with type 2 diabetes and liver fibrosis
- Conditions
- Hepatitis B, Chronic, Fibrosis, Liver, Diabetes Mellitus, Type 2
- Trial name
- NCT05473806
- Testing
- Pioglitazone 15 Mg Oral Tablet, Evogliptin 5mg
- Where
- 4 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Seung Up Kim
Chronic Hepatitis B Virus (Hbv)
Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)
Background: People who were born outside of the country are the largest group of adults infected with chronic hepatitis B virus (HBV) in the US. HBV affects the liver.
- Trial name
- NCT05621304
- Where
- 2 sites in United States
- Volunteers
- 274 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B, Chronic
A Prospective,Observational Follow-up Study of Nucleoside Treated Patients With Chronic Hepatitis B (OCEAN Study)
This is a prospective, multicentre observational follow-up study of PegIFN treatment unstained response in nucleoside experienced patients with Chronic Hepatitis B.Patients will join this study after finished following clinical…
- Trial name
- NCT03358108
- Where
- 11 sites in China
- Volunteers
- 1,600 people
- Sponsor
- Qin Ning
Chronic Hepatitis b, Liver Inflammation
Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B
This study evaluates the addition of glycyrrhizin to entecavir in the treatment of patients with chronic hepatitis B in China. Half of participants will receive magnesium isoglycyrrhizinate followed by oral diammonium…
- Trial name
- MAGIC-101 (NCT03349008)
- Testing
- Entecavir, Magnesium Isoglycyrrhizinate, Diammonium Glycyrrhizinate
- Volunteers
- 480 people
- Sponsor
- Cttq
Chronic Hepatitis B
A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate
This study is an open-label, ascending dose phase 1a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine
- Trial name
- NCT05727267
- Testing
- HEPLISAV B; TherVacB, TherVacB
- Where
- 2 sites in Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Hepatitis B Virus Infection, Children
Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B
This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with…
- Conditions
- Hepatitis B Virus Infection, Children, Chronic Hepatitis B
- Trial name
- NCT07345611
- Testing
- Entecavir, Entecavir + Pegylated interferon α-2b
- Volunteers
- 60 people
- Sponsor
- Qing-Lei Zeng
Hepatitis B Infection, Chronic Infection
Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus
To explore the antiviral effect of nucleoside analogue in late pregnancy and the safety of the antiviral drug to fetus.To establish the best therapy strategy to pregnant women with high level of HBV DNA.
- Conditions
- Hepatitis B Infection, Chronic Infection, Viremia
- Trial name
- NCT01788371
- Testing
- Telbivudine, Lamivudine
- Volunteers
- 700 people
- Sponsor
- Hua Zhang
Chronic HBV Infection (HBeAg Negative)
REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection
REP 2139-Ca is nucleic acid polymer. Nucleic acid polymers have been previously shown to clear serum hepatitis B virus surface antigen (HBsAg) both preclinically (in duck HBV infected ducks) and in human patients and to act…
- Trial name
- NCT02233075
- Testing
- REP 2139-Ca + Pegasys (TM)
- Where
- Moldova
- Volunteers
- 12 people
- Sponsor
- Replicor Inc.
Chronic Hepatitis B
A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB
This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs…
- Trial name
- NCT07095855
- Testing
- ZM-H1505R 100mg, NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF"） treatments
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Hepatitis B, Chronic, Hepatic Steatosis
Aerobic Exercise Training in Patients With Chronic Hepatitis B and Hepatic Steatosis
This study is a randomised, controlled, unblinded, clinical intervention trial consisting of 12 weeks of aerobic exercise training.
- Trial name
- FitLiver (NCT05265026)
- Testing
- High Intensity Interval Training
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chronic Hepatitis b
Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B
This is a Phase4, multicenter, open-label, randomized study to demonstrate that the Tenolid Tab switching group is non-inferior to the virologic suppression effect compared to the Viread Tab continuous administration group and…
- Trial name
- NCT05286346
- Testing
- Tenofovir disoproxil 245mg, Tenofovir disoproxil fumarate 300mg
- Where
- South Korea
- Volunteers
- 113 people
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
Hepatitis B
Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Therapy
The purpose of this study is to describe current rescue treatment pattern for nucleot(s)ide analogue (NA) resistance and assess the real-world treatment outcomes and health resources utilization of rescue treatments for drug…
- Trial name
- NAs resistance (NCT02791386)
- Where
- China
- Volunteers
- 383 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B
A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined with Pegylated Interferon in Subjects with Chronic Hepatitis B
- Trial name
- NCT04426968
- Testing
- Hepalatide 2.1mg, Hepalatide 4.2mg, Hepalatide 6.3mg
- Where
- 12 sites in China
- Volunteers
- 96 people
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Chronic Hepatitis B
Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)
The aim is to investigate whether Lamivudine 100mg daily is effective in the long term treatment of HBeAg negative chronic HBV infected patients with active liver disease in Asia
- Trial name
- NCT00338780
- Where
- China
- Sponsor
- Chinese University of Hong Kong
Chronic Hepatitis B, Hepatocellular Carcinoma
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common solid cancers worldwide, and chronic hepatitis B virus (HBV) infection is the most common etiology of HCC in Asia.
- Trial name
- NCT01872988
- Testing
- Tenofovir
- Where
- 4 sites in Taiwan
- Volunteers
- 320 people
- Sponsor
- Taichung Veterans General Hospital
Hepatitis B, Chronic
Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253
This study will evaluate immune responses in patients with HBeAg-negative chronic Hepatitis B treated with Pegasys (peginterferon alfa-2a).
- Trial name
- NCT01237496
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 5 sites in Italy
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China
This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.
- Trial name
- NCT04507269
- Testing
- VIR-2218
- Where
- 2 sites in China
- Volunteers
- 21 people
- Sponsor
- Brii Biosciences Limited
Chronic Hepatitis B Infection
The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03209037
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis B, Chronic
A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB
This is a multicenter, randomized, double-blind, placebo-controlled phase IIa study, designed to evaluate the efficacy and safety of ZM-H1505R in combination with Baraclude versus Baraclude monotherapy in adult CHB subjects with…
- Trial name
- NCT05484466
- Testing
- ZM-H1505R, Baraclude
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
HBV Related Acute-on-chronic Liver Failure, HBV-related Liver Cirrhosis
Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure
This study aims to investigate the methylomic features of patients with hepatitis B-related acute-on-chronic liver failure and establish and validate a prognostic risk prediction classification model.
- Conditions
- HBV Related Acute-on-chronic Liver Failure, HBV-related Liver Cirrhosis, HBV (Hepatitis B Virus)
- Trial name
- NCT07275554
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Hospital of Shandong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.